Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ventiv Dermatology Sales Force To Promote Ranbaxy’s Isotretinoin

This article was originally published in The Pink Sheet Daily

Executive Summary

The firms sign multi-year agreement to market Sotret. Ventiv says it has established a specialty dermatology sales force to promote the product.

You may also be interested in...

Watson Seeks Co-Promotion Partner For Oxytrol In Primary Care Setting

The company is seeking a partner with "strong relationships" with high-volume prescribers of overactive bladder therapies in the primary care market. Watson wants to retain Oxytrol's position in primary care despite the company's intention to shift its marketing focus to specialty care.

Accutane Risk Management Program Changes Held Up By Celgene Patents

Four patents relating to the STEPS risk management program for Thalomid are an “obstacle” to implementing an augmented isotretinoin program, FDA says. The agency’s Office of Chief Counsel is reviewing the issue.

Accutane/Generics Risk Program Should Include Mandatory Follow-Up Survey

FDA advisory committee suggests  enhancements to Roche's SMART program to better prevent pregnancies. The proposal calls for a shared brand/generic system for patient registration.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts